Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program
Provided By GlobeNewswire
Last update: Feb 18, 2025
First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025
New 12-month data on the first three adult OPGx-LCA5 patients to be presented at a major medical conference in Q2 2025
FDA meeting scheduled in March 2025 to discuss Phase 3 trial design and registrational endpoints for OPGx-LCA5
